Therapeutic Potentials and Candidates for COVID-19

被引:0
|
作者
Mina Rezghi Rami
Maryam Meskini
Nahid Rezaei Khozani
Shayan Forouzandehdel
Saeideh Momtaz
Soumya Ghosh
Nima Rezaei
Amir Hossein Abdolghaffari
机构
[1] K. N. Toosi University of Technology,Department of Chemistry
[2] Pasteur Institute of Iran,Mycobacteriology & Pulmonary Research Department
[3] Pasteur Institute of Iran,Microbiology Research Center
[4] Universal Scientific Education and Research Network (USERN),Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA)
[5] Kashan University of Medical Science,Department of Microbiology, Faculty of Medicine
[6] Sharif University of Technology,Department of Chemistry
[7] ACECR,Medicinal Plants Research Center, Institute of Medicinal Plants
[8] Tehran University of Medical Sciences,Toxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), and Department of Toxicology and Pharmacology, School of Pharmacy
[9] Universal Scientific Education and Research Network (USERN),Gastrointestinal Pharmacology Interest Group (GPIG)
[10] University of the Free State,Department of Genetics, Faculty of Natural and Agricultural Sciences
[11] Tehran University of Medical Sciences,Research Center for Immunodeficiencies, Children’s Medical Center
[12] Tehran University of Medical Sciences,Department of Immunology, School of Medicine
[13] Tehran Medical Sciences,Department of Toxicology & Pharmacology, Faculty of Pharmacy
[14] Islamic Azad University,undefined
来源
关键词
COVID-19; Coronavirus disease 2019; SARS-CoV-2; Treatment; Drug repurposing;
D O I
暂无
中图分类号
学科分类号
摘要
The current coronavirus disease 2019 (COVID-19) outbreak spread rapidly worldwide. Yet, there is no identifiable antiviral treatment, so an effective drug is urgently needed. Preventive strategies and oxygen therapy are the main practical approaches to prevent and treat COVID-19. Clinical trials are in progress for the antiviral and immunomodulation agents that eventually are being developed for COVID-19 treatment. Pharmacological, immunotherapies, natural-based supplements, biologics, and combination therapies interventions have been established. The concept of drug repurposing was re-visited, and many conventional antivirals or immunosuppresses were evaluated for Efficacy against COVID-19 infection. Even though much has been published, the rapid progression of therapeutic strategies and unpredictable disease alterations necessitates continual information updates. This review defines drug repurposing and summarizes a medication developed for other therapeutic approaches rather than SARS-CoV-2 treatment. Furthermore, we provide data on the effectiveness of traditional Chinese medicines (TCM) on COVID-19. Additionally, biological and advanced Nano-based drug delivery systems are reviewed.
引用
收藏
页码:1283 / 1297
页数:14
相关论文
共 50 条
  • [31] COVID-19: The Immune Responses and Clinical Therapy Candidates
    Zhand, Sareh
    Saghaeian Jazi, Marie
    Mohammadi, Saeed
    Tarighati Rasekhi, Roozbeh
    Rostamian, Ghassem
    Kalani, Mohammad Reza
    Rostamian, Aida
    George, Jacob
    Douglas, Mark W.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (15) : 1 - 34
  • [32] Therapeutic prospects of ceRNAs in COVID-19
    Liu, Lin
    Zhang, Yao
    Chen, Yu
    Zhao, Yueshui
    Shen, Jing
    Wu, Xu
    Li, Mingxing
    Chen, Meijuan
    Li, Xiaobing
    Sun, Yuhong
    Gu, Li
    Li, Wanping
    Wang, Fang
    Yao, Lei
    Zhang, Zhuo
    Xiao, Zhangang
    Du, Fukuan
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 12
  • [33] Therapeutic Options for COVID-19: A Review
    Pujari, Rishita
    Thommana, Mary, V
    Mercedes, Brisandi Ruiz
    Serwat, Ayna
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (09)
  • [34] Emerging Therapeutic Options for COVID-19
    Khubchandani, Sheetal Rameshlal
    Dahane, Trupti Madhav
    JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS, 2020, 9 (41): : 3082 - 3085
  • [35] Precision therapeutic targets for COVID-19
    Zachary A. Krumm
    Grace M. Lloyd
    Connor P. Francis
    Lith H. Nasif
    Duane A. Mitchell
    Todd E. Golde
    Benoit I. Giasson
    Yuxing Xia
    Virology Journal, 18
  • [36] An Antioxidant Enzyme Therapeutic for COVID-19
    Qin, Meng
    Cao, Zheng
    Wen, Jing
    Yu, Qingsong
    Liu, Chaoyong
    Wang, Fang
    Zhang, Jianjun
    Yang, Fengmei
    Li, Yanyan
    Fishbein, Gregory
    Yan, Sen
    Xu, Bin
    Hou, Yi
    Ning, Zhenbo
    Nie, Kaili
    Jiang, Ni
    Liu, Zhen
    Wu, Jun
    Yu, Yanting
    Li, Heng
    Zheng, Huiwen
    Li, Jing
    Jin, Weihua
    Pang, Shen
    Wang, Shuai
    Chen, Jianfeng
    Gan, Zhihua
    He, Zhanlong
    Lu, Yunfeng
    ADVANCED MATERIALS, 2020, 32 (43)
  • [37] Emerging Therapeutic Approaches to COVID-19
    Singh, Indrakant K.
    Kumari, Pratibha
    Mittal, Pooja
    Kumar, Amit
    Singal, Bharti
    Hasan, Gulam M.
    Aggarwal, Rajiv
    Kamal, Md. Amjad
    Singh, Archana
    Hassan, Md. Imtaiyaz
    CURRENT PHARMACEUTICAL DESIGN, 2021, 27 (31) : 3370 - 3388
  • [38] Precision therapeutic targets for COVID-19
    Krumm, Zachary A.
    Lloyd, Grace M.
    Francis, Connor P.
    Nasif, Lith H.
    Mitchell, Duane A.
    Golde, Todd E.
    Giasson, Benoit, I
    Xia, Yuxing
    VIROLOGY JOURNAL, 2021, 18 (01)
  • [39] Therapeutic anticoagulation in COVID-19 patients
    Lemos, Anna Cristina Bertoldi
    Santo, Douglas Alexandre do Espirito
    Miranda, Carlos Henrique
    THROMBOSIS RESEARCH, 2021, 203 : 72 - 73
  • [40] The epidemiology and therapeutic options for the COVID-19
    Li, Jingwei
    Shao, Jun
    Wang, Chengdi
    Li, Weimin
    PRECISION CLINICAL MEDICINE, 2020, 3 (02) : 71 - 84